{'Year': '2015'}
FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis.
The aim of our study was to explore the potential of FcGR genetic polymorphisms as a predictor of adalimumab efficacy in rheumatoid arthritis (RA) patients.